Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases

Shih En Tseng, Yi You Chiou, Yu Chin Lee, Reury Perng Perng, Whang Peng Jacqueline, Yuh Min Chen

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Background: In patients with non-small cell lung cancer (NSCLC), the development of liver metastasis (LM) is a poor prognostic factor. Whether systemic treatment combined with local treatment for LM has benefit for NSCLC patients with LM is unknown. Methods: We retrospectively reviewed and analyzed the clinical data and tumor epidermal growth factor receptor (. EGFR) mutation status of 673 pulmonary adenocarcinoma patients, including 85 patients who developed LM at any time point in the course of the disease. Radiofrequency ablation (RFA) with real-time ultrasonographic guidance was used for local treatment of LM in these patients, if appropriate. Results: Patients with an EGFR mutation were more prone to having synchronous LM than patients with EGFR wild-type (50.0% vs. 23.5%, P=. 0.019). Fifty-six patients (65.9%) had ≦5 LM nodules. The median overall survival (OS) of patients with ≦5 LM nodules was 7.6 months compared with 2.9 months for those with multiple nodules (. P<. 0.001). The independent prognostic factors after LM were performance status, EGFR mutation, synchronous LM and LM numbers. The independent prognostic factors for patients with ≦5 LM nodules were performance status, EGFR mutation, LM concomitant with adrenal metastasis and having received RFA. Patients who received RFA treatment (. n=. 6) had longer OS after LM than those without RFA treatment (. n=. 42) (23.1 vs. 7.9 months, P=. 0.035). Conclusions: We recommend that patients with a better performance status and ≦5 LM nodules be considered for systemic treatment combined with RFA when LM develops.
原文英語
頁(從 - 到)225-230
頁數6
期刊Lung Cancer
86
發行號2
DOIs
出版狀態已發佈 - 一月 1 2014

指紋

Neoplasm Metastasis
Liver
Therapeutics
Adenocarcinoma of lung
Mutation
Non-Small Cell Lung Carcinoma
Survival
Liver Neoplasms
Epidermal Growth Factor Receptor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

引用此文

Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. / Tseng, Shih En; Chiou, Yi You; Lee, Yu Chin; Perng, Reury Perng; Jacqueline, Whang Peng; Chen, Yuh Min.

於: Lung Cancer, 卷 86, 編號 2, 01.01.2014, p. 225-230.

研究成果: 雜誌貢獻文章

Tseng, Shih En ; Chiou, Yi You ; Lee, Yu Chin ; Perng, Reury Perng ; Jacqueline, Whang Peng ; Chen, Yuh Min. / Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. 於: Lung Cancer. 2014 ; 卷 86, 編號 2. 頁 225-230.
@article{7703005db5084afc8348347fb613c9bb,
title = "Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases",
abstract = "Background: In patients with non-small cell lung cancer (NSCLC), the development of liver metastasis (LM) is a poor prognostic factor. Whether systemic treatment combined with local treatment for LM has benefit for NSCLC patients with LM is unknown. Methods: We retrospectively reviewed and analyzed the clinical data and tumor epidermal growth factor receptor (. EGFR) mutation status of 673 pulmonary adenocarcinoma patients, including 85 patients who developed LM at any time point in the course of the disease. Radiofrequency ablation (RFA) with real-time ultrasonographic guidance was used for local treatment of LM in these patients, if appropriate. Results: Patients with an EGFR mutation were more prone to having synchronous LM than patients with EGFR wild-type (50.0{\%} vs. 23.5{\%}, P=. 0.019). Fifty-six patients (65.9{\%}) had ≦5 LM nodules. The median overall survival (OS) of patients with ≦5 LM nodules was 7.6 months compared with 2.9 months for those with multiple nodules (. P<. 0.001). The independent prognostic factors after LM were performance status, EGFR mutation, synchronous LM and LM numbers. The independent prognostic factors for patients with ≦5 LM nodules were performance status, EGFR mutation, LM concomitant with adrenal metastasis and having received RFA. Patients who received RFA treatment (. n=. 6) had longer OS after LM than those without RFA treatment (. n=. 42) (23.1 vs. 7.9 months, P=. 0.035). Conclusions: We recommend that patients with a better performance status and ≦5 LM nodules be considered for systemic treatment combined with RFA when LM develops.",
keywords = "Epidermal growth factor receptor (EGFR), Liver metastasis, Prognostic factors, Pulmonary adenocarcinoma, Radiofrequency ablation (RFA), Survival",
author = "Tseng, {Shih En} and Chiou, {Yi You} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline, {Whang Peng} and Chen, {Yuh Min}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.lungcan.2014.09.002",
language = "English",
volume = "86",
pages = "225--230",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases

AU - Tseng, Shih En

AU - Chiou, Yi You

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Jacqueline, Whang Peng

AU - Chen, Yuh Min

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: In patients with non-small cell lung cancer (NSCLC), the development of liver metastasis (LM) is a poor prognostic factor. Whether systemic treatment combined with local treatment for LM has benefit for NSCLC patients with LM is unknown. Methods: We retrospectively reviewed and analyzed the clinical data and tumor epidermal growth factor receptor (. EGFR) mutation status of 673 pulmonary adenocarcinoma patients, including 85 patients who developed LM at any time point in the course of the disease. Radiofrequency ablation (RFA) with real-time ultrasonographic guidance was used for local treatment of LM in these patients, if appropriate. Results: Patients with an EGFR mutation were more prone to having synchronous LM than patients with EGFR wild-type (50.0% vs. 23.5%, P=. 0.019). Fifty-six patients (65.9%) had ≦5 LM nodules. The median overall survival (OS) of patients with ≦5 LM nodules was 7.6 months compared with 2.9 months for those with multiple nodules (. P<. 0.001). The independent prognostic factors after LM were performance status, EGFR mutation, synchronous LM and LM numbers. The independent prognostic factors for patients with ≦5 LM nodules were performance status, EGFR mutation, LM concomitant with adrenal metastasis and having received RFA. Patients who received RFA treatment (. n=. 6) had longer OS after LM than those without RFA treatment (. n=. 42) (23.1 vs. 7.9 months, P=. 0.035). Conclusions: We recommend that patients with a better performance status and ≦5 LM nodules be considered for systemic treatment combined with RFA when LM develops.

AB - Background: In patients with non-small cell lung cancer (NSCLC), the development of liver metastasis (LM) is a poor prognostic factor. Whether systemic treatment combined with local treatment for LM has benefit for NSCLC patients with LM is unknown. Methods: We retrospectively reviewed and analyzed the clinical data and tumor epidermal growth factor receptor (. EGFR) mutation status of 673 pulmonary adenocarcinoma patients, including 85 patients who developed LM at any time point in the course of the disease. Radiofrequency ablation (RFA) with real-time ultrasonographic guidance was used for local treatment of LM in these patients, if appropriate. Results: Patients with an EGFR mutation were more prone to having synchronous LM than patients with EGFR wild-type (50.0% vs. 23.5%, P=. 0.019). Fifty-six patients (65.9%) had ≦5 LM nodules. The median overall survival (OS) of patients with ≦5 LM nodules was 7.6 months compared with 2.9 months for those with multiple nodules (. P<. 0.001). The independent prognostic factors after LM were performance status, EGFR mutation, synchronous LM and LM numbers. The independent prognostic factors for patients with ≦5 LM nodules were performance status, EGFR mutation, LM concomitant with adrenal metastasis and having received RFA. Patients who received RFA treatment (. n=. 6) had longer OS after LM than those without RFA treatment (. n=. 42) (23.1 vs. 7.9 months, P=. 0.035). Conclusions: We recommend that patients with a better performance status and ≦5 LM nodules be considered for systemic treatment combined with RFA when LM develops.

KW - Epidermal growth factor receptor (EGFR)

KW - Liver metastasis

KW - Prognostic factors

KW - Pulmonary adenocarcinoma

KW - Radiofrequency ablation (RFA)

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84908403505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908403505&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.09.002

DO - 10.1016/j.lungcan.2014.09.002

M3 - Article

C2 - 25240517

AN - SCOPUS:84908403505

VL - 86

SP - 225

EP - 230

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -